Uterine carcinosarcoma: An overview.

Gaetano Pezzicoli, Francesca Moscaritolo, Erica Silvestris, Franco Silvestris, Gennaro Cormio, Camillo Porta, Stella D'Oronzo

Research output: Contribution to journalReview articlepeer-review


Uterine carcinosarcoma (UCS), also known as malignant mixed Müllerian tumor, is a rare gynecological malignancy characterized by poor prognosis. This “biphasic” neoplasm presents an admixture of epithelial and mesenchymal/sarcomatoid tumor cells which partially share their molecular signature and exhibit a typical epithelial-to-mesenchymal transition gene expression profile. Due to the rarity of this cancer, at present there is a scarcity of specific treatment guidelines. Surgical resection remains the best curative option for localized disease, whereas the addition of peri-operative radiotherapy, chemotherapy and chemoradiation has been shown to further improve disease outcomes. In the metastatic setting, palliative chemotherapy is currently the treatment of choice, although no consensus exists about the best regimen to be delivered. Besides standard treatment options for the advanced disease, mechanistic insights into UCS pathogenesis and identification of its histopathological and molecular features boosted the development of novel, and potentially more effective, therapeutic agents, that will be here discussed.

Original languageEnglish
Article number103369
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - May 27 2021


  • Biphasic tumor
  • Epithelial-to-mesenchymal transition
  • Malignant mixed Müllerian tumor
  • Uterine carcinosarcoma

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Uterine carcinosarcoma: An overview.'. Together they form a unique fingerprint.

Cite this